BioSkryb obtains an exclusive license for single-cell methylation patent

BioSkryb Genomics has obtained an exclusive license to a patent developed by Stanford and the Chan Zuckerberg Biohub that enables combined DNA methylation and genomic variant analysis in a single cell. This technology represents a significant advancement in genomics, enabling researchers to track clonal evolution, treatment resistance, and rare cell biology without compromising DNA integrity.

Furthermore, BioSkryb envisions a modular workflow that will integrate the genome, epigenome, transcriptome, and surface proteome in a single cell, advancing a more integrated and efficient precision medicine. To help customers interpret these discoveries, the company is also investing in AI and machine learning to integrate single-cell multi-omics data into interpretable features and novel biomarker candidates — an emerging need as single-cell multi-omics datasets grow in scale and complexity.

DNA methylation

Read more:

https://www.bioskryb.com/news/exclusive-license/